Products for Research Use Only
RegisterLogin

NP1192

CAT: 0804-HY-178360Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178360Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NP1192 is a potent, selective PROTAC NAT10 degrader that depletes NAT10 protein and inhibits ac4C modification in cancer cells. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research. (Blue: CRBN ligand ; Black: linker; Pink: NAT10 ligand (HY-16706) ).
CAS Number
2966791-41-1
UNSPSC
12352005
Target
HIF/HIF Prolyl-Hydroxylase; Histone Acetyltransferase; PD-1/PD-L1; PROTACs; PTEN
Related Pathways
Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; PROTAC
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Smiles
N#CC1=CC=C(C=C1)C2=CSC(N(/N=C3CCCC/3)CCCCCCC(N4CCN(CC4)C5=C6C(N(C(C6=CC=C5)=O)C7CCC(NC7=O)=O)=O)=O)=N2
Molecular Formula
C39H42N8O5S
Molecular Weight
734.87
References & Citations
[1]Ao, K., et al. Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8+ Effector T-Cell Function for Synergistic Cancer Immunotherapy. ACS Central Science. 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-131347-01PD-1/PD-L1-IN-NP19

Alternative Products

CatalogName
GTR19275137-01NP1192

Popular Products